Suchen Sie nach Informationen zu Biocon Unternehmenszentrale? Folgen Sie den Links unten, um alle Informationen zu finden, die Sie benötigen, und mehr.
Biocon Biologics issues a statement in response to the media reports related to bribery allegations. Tue, 21-Jun-2022 Details. Biocon Biologics Denies Bribery Allegations. Tue, 21-Jun-2022 Details. MORE >>. Insulin Glargine: Journey to the historic U.S. approval for the first interchangeable biosimilar. Biocon Biologics Global Scale Capabilities.
https://www.biocon.com/businesses/
Path-breaking offerings. Far-reaching impact. Our global businesses – generics, biosimilars, research services and novel biologics research, develop and manufacture innovative biopharmaceutical medicines for unmet medical needs and branded formulations cater to the Indian market. We truly believe drug innovation and therapy cost must interact ...
https://www.biocon.com/careers/
Put your passion. for science into practice. Working with one of the world’s most advanced biopharmaceutical companies brings with it a tremendous opportunity to create a lasting impact on global health. It’s a chance to work alongside some of the brightest minds in research, healthcare, pharmaceutical, biotechnology and business sectors.
https://www.biocon.com/investor-relations/
OVERVIEW. Biocon is a unique global biopharmaceutical company changing patients’ lives in over 120 countries. From drug discovery to drug delivery, we make life-saving medicines for the most feared diseases, to extend and significantly improve the quality of life.
https://www.biocon.com/investor-relations/corporate-governance/corporate-structure/
Biocon Corporate and Subsidiary Group structure. Syngene, Biocon Biologics, Biocon Pharma, Biocon Academy, Biocon Biosphere, Neo Biocon...
https://www.biocon.com/biocon-biologics-and-serum-institute-life-sciences-announce-strategic-alliance/
Bengaluru, Karnataka, India – September 16, 2021. Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. and Serum Institute Life Sciences Private Limited (SILS), a subsidiary of Serum Institute of India Pvt. Ltd. today announced a strategic alliance. Under the terms of the agreement, BBL will offer approximately 15% stake to SILS, at a ...
Biocon is a global biopharmaceutical company. It manufactures biologics, biosimilar insulins, and antibodies. The company focuses on the areas of diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology, and inflammatory diseases. It is also involved in the integrated discovery, development, and manufacturing services ...
https://www.biocon.com/investor-relations/financial-information/
Access Financial Information - Annual & Quarterly Reports, Key Figures, Earnings Call Transcript, Subsidiary Financial, Investor Presentation
https://www.biocon.com/investor-relations/contact-investors-relation/
E [email protected]. T +91 – (80) – 2808 2808 F +91 – (80) – 2852 3423 . Financial Institutions, Brokerage Firms and Financial Analysts: Ms. Aishwarya Sitharam Head, Investor Relations E [email protected] E [email protected] T +91 80 2808 2083 . Corporate Governance, Shareholder Grievance Redressal & Retail ...
http://biospace.biocon.com/
Wir hoffen, dass Sie über die obigen Links alle notwendigen Informationen zu Biocon Unternehmenszentrale gefunden haben.
